Prosecution Insights
Last updated: November 20, 2026
Application No. 17/777,741

COMPOSITIONS AND METHODS OF USING ENGINEERED FUSION PROTEINS THAT BIND G4C2 HUMAN REPEATS

Non-Final OA §103§112
Filed
May 18, 2022
Priority
Nov 19, 2019 — provisional 62/937,468 +3 more
Examiner
BURKHART, MICHAEL D
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
5 (Non-Final)
62%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
531 granted / 850 resolved
+2.5% vs TC avg
Moderate +12% lift
Without
With
+11.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
35 currently pending
Career history
890
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
28.4%
-11.6% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
26.4%
-13.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 850 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 3-5, 7, 8, 13, 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites the limitation "the first and second sequences" in line 5. There is insufficient antecedent basis for this limitation in the claim. This rejection effects all dependent claims. *** Dependent claims 3, 7 and 8 also recite “the first sequence” or “the second sequence”.*** The rejection of the claims as lacking written description is withdrawn in light of amendment of the claims to recite specific SEQ ID NOs comprising the recited fused domains. Claim Rejections - 35 USC § 103 The rejection of the claims as obvious is withdrawn in light of amendment of the claims to recite specific SEQ ID NOs comprising the recited fused domains. The recited SEQ ID NOs are not taught or suggested by the cited prior art. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Burkhart whose telephone number is (571)272-2915. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571 272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL D BURKHART/Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Show 7 earlier events
Apr 14, 2026
Response Filed
Jun 03, 2026
Final Rejection mailed — §103, §112
Jul 22, 2026
Applicant Interview (Telephonic)
Jul 22, 2026
Examiner Interview Summary
Aug 31, 2026
Response after Non-Final Action
Sep 29, 2026
Request for Continued Examination
Oct 06, 2026
Response after Non-Final Action
Nov 04, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799182
CIRCULAR RNA COMPOSITIONS AND METHODS
3y 11m to grant Granted Nov 17, 2026
Patent 12799168
SIGNAL SEQUENCE THAT INDUCES PROTEIN SECRETION IN INTESTINAL MICROBIOME
3y 1m to grant Granted Nov 17, 2026
Patent 12781197
METHODS AND COMPOSITIONS FOR THE PURIFICATION OF ADENO-ASSOCIATED VIRUS
4y 0m to grant Granted Nov 03, 2026
Patent 12774317
HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
3y 1m to grant Granted Oct 27, 2026
Patent 12754124
Hematological Parameter for Viral Infection
3y 11m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
62%
Grant Probability
74%
With Interview (+11.8%)
3y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 850 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month